CSPC Pharmaceutical Group Limited
https://www.cspc.com.hk/en/global/home.php
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSPC Pharmaceutical Group Limited
Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Tough Going Forces Chinese Biotechs To Form Domestic Alliances
Deals among domestic Chinese biotechs are growing fast, reflecting a need to huddle up amid tightening scrutiny over biotech deal-making and an unusually competitive immuno-oncology market.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Large Molecule
- Other Names / Subsidiaries
-
- NovaRock Biotherapeutics, Shijiazhuang Pharma Group
- China Shijiazhuang Pharmaceutical Group Co Ltd
- Hong Kong Tainuo Pharma Ltd
- Jiangsu Tainuo Pharmaceutical Co Ltd
- CSPC Pharmaceutical Group Co., Ltd.
- JMT-Bio
- Shanghai Jinmante Biotechnology Co., Ltd.